Influence of size, surface coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models

Samuli Hirsjärvi, Sandrine Dufort, Julien Gravier, Isabelle Texier, Qiao Yan, Jérôme Bibette, Lucie Sancey, Veronique Josserand, Catherine Passirani-Malleret, Jean-Pierre Benoit, et al.

► To cite this version:

Samuli Hirsjärvi, Sandrine Dufort, Julien Gravier, Isabelle Texier, Qiao Yan, et al.. Influence of size, surface coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models. *Nanomedicine: Nanotechnology, Biology and Medicine*, 2013, 9 (3), pp.375-87. 10.1016/j.nano.2012.08.005 . hal-03180818

HAL Id: hal-03180818

<https://univ-angers.hal.science/hal-03180818>

Submitted on 25 Mar 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ELSEVIER

Influence of size, surface coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models

Samuli Hirsjärvi, PhD^{c,1}, Sandrine Dufort, PhD^{a,b,1}, Julien Gravier, PhD^{d,1},
Isabelle Texier, PhD^d, Qiao Yan, PhD^e, Jérôme Bibette, PhD^e, Lucie Sancey, PhD^{a,b},
Véronique Josserand, PhD^{a,b}, Catherine Passirani, PhD^c,
Jean-Pierre Benoit, PhD^c, Jean-Luc Coll, PhD^{a,b,*}

^aINSERM U823, Institut Albert Bonniot, 38 706 Grenoble, France

^bUniversité Joseph Fourier, Grenoble, France

^cINSERM U646, Angers, France

^dCEA, LETI/DTBS, Grenoble, France

^eESPCI, Paris, France

Received 20 January 2012; accepted 8 August 2012

Abstract

Lipid nanocapsules (LNCs) and lipid nanoemulsions (LNEs) are biomimetic synthetic nanocarriers. Their in vitro and in vivo performance was evaluated as a function of their size (25, 50 and 100 nm) and the surface PEG chain length. Analysis methods included complement activation test, particle uptake in macrophage and HEK293(β3) cells and biodistribution studies with tumor-grafted mice by fluorescence imaging. A particular attention was paid to keep the concentration of each nanocarrier and to the amount of fluorescent dye in comparable conditions between the in vitro and in vivo studies. Under these conditions, no significant differences were found among the three tested particle sizes and the two nanocarrier types. Longer PEG chains on the LNE surface provided better stealth properties, whereas PEG modification on the LNC formulations inhibited the production of stable nanocarriers. Passive accumulation of LNCs and LNEs in different tumor types depended on the degree of tumor vascularization.

From the Clinical Editor: This study of lipid nanocapsules and lipid nanoemulsions compares their vitro and in vivo performance as a function of size and surface PEG chain length, demonstrating no significant difference among the tested particle sizes. Longer PEG chains on the LNE surface provided better stealth properties, whereas PEG modification on the LNC formulations inhibited the production of stable nanocarriers. © 2013 Elsevier Inc. All rights reserved.

Key words: Biocompatible materials; Biodistribution; Lipid nanocarriers; Nanoparticles; Near-infrared optical imaging

Sources of support for research: This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), the University Joseph Fourier Grenoble 1, the Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), the cancéropole CLARA, the INCA (Institut National for Cancer), and the French National Research Agency (ANR) in the frame of its programme in Nanosciences and Nanotechnologies (CALIF project no. ANR-08-NANO-006). S. Hirsjärvi acknowledges Academy of Finland for funding.

*Corresponding author: INSERM-UJF U823, Institut Albert Bonniot, 38706 Grenoble, France.

E-mail address: Jean-Luc.Coll@ujf-grenoble.fr (J.-L. Coll).

¹ These three authors contributed equally.

Lipid nanocapsules (LNCs)^{1–3} and lipid nanoemulsions (LNEs)^{4–7} are two types of synthetic particles, with tunable diameters ranging between 25 and 100 nm that offer versatility for the delivery of drugs,^{8–12} DNA,^{13,14} radiotherapeutics^{15–17} and imaging agents.^{18,19}

They are spherical, made of biocompatible materials, and exhibit good dispersion stability. Their surfaces contain polyethylene glycol (PEG) chains that provide stealth properties. They are both produced in solvent-free conditions, using easily scalable processes: LNCs are prepared by a low-energy phase inversion temperature method, while LNEs are formed using homogenization by

Figure 1. Schematic presentation of the LNC (A) and LNE (B) preparation methods, and the structures of LNCs and LNEs (C). The major difference between LNCs and LNEs is coming from the type of energy provided for their formation: heating is used for LNCs and sonication for LNEs. LNCs are expected to be more rigid than LNEs.

ultrasonication (Figure 1). Both LNCs and LNEs can be characterized as hybrids of micelles (with a swollen lipid core) and polymer nanocapsules (shell consisting of a mixture of lecithin and a PEGylated surfactant). However, although their structures are similar, they present subtle differences (Supplementary Figure 1, available online at <http://www.nanomedjournal.com>). LNCs have a fairly rigid shell that stably anchors the PEGylated surfactant in the lipid core. In comparison, the LNE shell surfactant is more mobile. The particle's stability is ensured by the low water solubility of the lipid core and the use of a complex lipid/surfactant structure that increases the particle's entropic stability.⁶ The length of the PEG chains can also be modified to decrease protein adsorption and increase the stealth properties of nanocarriers because PEG chain length is correlated with protein adsorption and stealth characteristics.²⁰

Their size ranging from 25 to 100 nm favors their accumulation in tumors via the enhanced permeability and retention (EPR) effect.²¹ LNCs and LNEs are thus powerful tools for studying how physicochemical variations can influence nanocarrier biodistribution in vivo.

In this study, we evaluated the pharmacokinetics and organ/tissue distribution of fluorescent LNCs and LNEs. The effects of nanocarrier diameter (25, 50 and 100 nm) and surface modification by different PEG chains were assessed. The following methods were used for in vitro evaluation: the CH50 complement activation test and particle uptake studies using macrophage (THP-1) and HEK293(β3) cells. The HEK293(β3) cells are a human embryonic kidney cell line that overexpresses α_vβ₃ integrins, making them a good model for nanocarriers grafted with RGD-type targeting peptides.^{7,22} In vivo biodistribution studies were performed with mice with HEK293 tumors, in addition to three other tumor models that exhibited various degrees of vascularization.

Methods

Materials

Solutol HS15 (PEG 660 12-hydroxystearate) was a gift from BASF (Ludwigshafen, Germany) and stearate of PEG 1500 (DUB S PEG 30 S) was donated by Stéarinerie Dubois (Boulogne

Billancourt, France). Myr 53 (PEG 40 stearate, 1980 Da), Myrj 49P (PEG 20 stearate, 800 Da), and Super Refined Soybean Oil were obtained from Croda Uniquema (Chocques, France). Labrafac WL 1349 (caprylic/capric acid triglycerides) and Suppocire NC were bought from Gattefossé S.A. (Saint-Priest, France), and Lipoid S75-3 (lecithin with more than 75% phosphatidylcholine) was bought from Lipoid GmbH (Ludwigshafen, Germany). MilliQ185 water (Waters, Saint-Quentin-en-Yveline, France) was used in all experiments. The fluorescent dye, DiD (1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine perchlorate), was obtained from Invitrogen (Cergy Pontoise, France). All other reagents were of analytical grade.

Preparation of LNCs and LNEs

LNCs were prepared according to the phase inversion temperature method described by Heurtault et al.¹ (Figure 1). Briefly, a mixture of Solutol (or PEG 1500), Lipoid, Labrafac, NaCl (5% in water) and water was heated to 85 °C (95 °C with the PEG 1500 formulation) at a rate of 5 °C/min, followed by cooling at the same rate to 65 °C. This cycle was repeated twice. When the mixture reached 78 °C (85 °C with the SPEG 1500 formulation) during the phase inversion zone of the last cooling cycle, the system was diluted with cold (0 °C) water, leading to formation of stable LNCs. Fluorescent dye (DiD), dissolved in acetone, was added to the formulation vial, followed by evaporation of the acetone before adding the LNC components. The final local dye concentration in the nanocarriers was approximately 1.2 mM. The LNC dispersions were filtered through 0.22 µm filters (Minisart High-Flow, Sartorius Stedim Biotech, Goettingen, Germany).

LNEs were prepared as described by Goutayer et al.⁴ (Figure 1). 80 µL of 10 mM dye solution in CH₂Cl₂ was poured into a 5 ml vial, for a final dye concentration in the nanocarriers of about 1.2 mM. The solvent was evaporated under vacuum before the oil premix (Soybean oil, Suppocire NC and Lipoid) was added. Myrj 53 or Myrj 49P was dissolved in 154 mM NaCl aqueous solution and added to the oily premix. The mixture was placed in a 60 °C water bath and sonicated for 5 min using a VCX750 Ultrasonic processor (power output 190 W, probe diameter 3 mm, Sonics, Newtown). LNEs were dialyzed overnight at room temperature against an aqueous buffer (M_wCO 12–14 kDa membranes, ZelluTrans) and filtered through 0.22 µm filters (Minisart High-Flow, Sartorius Stedim Biotech, Goettingen, Germany).

The size of both nanocarriers could be adjusted by changing the proportions of the components (see supplementary Table 1). For a given PEG length, three sizes were formulated: 25 nm, 50 nm, and 100 nm. Another PEG length (1500 Da for LNC; 880 Da for LNE) was tested with 50 nm particles.

Characterization of LNCs and LNEs

Size distributions and zeta (ζ) potentials were determined using a Zetasizer ZS (Malvern, Worcestershire, United Kingdom). Particle sizing was based on photon correlation spectroscopy (PCS); the results were analyzed by the CONTIN algorithm, and the sizes were presented based on the volume distributions and the polydispersity indices (PDI). PDI is a

dimensionless value that represents the width of the particle size distribution. Electrophoretic mobilities were converted to ζ-potentials using Smoluchowski's equation.

Complement activation evaluation

Complement consumption was assessed in normal human serum (Etablissement Francais du Sang, Angers, France). The residual haemolytic capacity of the complement system was measured after contact with LNCs or LNEs. Poly(methyl methacrylate) (PMMA) nanoparticles, strong complement activators,²³ were used as a positive control. This technique determines the amount of serum needed to lyse 50% of a fixed number of sheep erythrocytes (CH50) that were previously sensitized by rabbit anti-sheep erythrocyte antibodies, as described elsewhere.²⁴ Complement activation was expressed as a function of the LNC/LNE surface area, in order to compare particles of different diameters. Nanoparticle surface areas were calculated using the following equations: $S = n4\pi r^2$ and $V = n(4/3)(\pi r^3)$, leading to $S = 3m/r\rho$, where S was the surface area (cm²) and V was the volume (cm³) of n spherical particles of average radius r (cm), m was the weight (µg) and ρ was the volumetric mass (µg/cm³).²³ All experiments were performed in triplicate.

Uptake by THP-1 and HEK293(β3) cells

THP-1 cells (human monocyte/macrophage cell line, ATCC, Manassas, VA, USA) were grown in suspension in a humidifier-incubator (5% CO₂) at 37 °C, in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES, 1 mM sodium pyruvate, 1.5 g/L bicarbonate (Lonza, Verviers, Belgium), 0.05 mM 2-mercaptoethanol, and 100 U/mL penicillin G and 100 µg/mL streptomycin (Sigma, Saint-Quentin Fallavier, France). Cells were harvested and counted using the Trypan blue exclusion assay. Approximately 5×10^5 cells/500 µL were seeded in sterile 24-well cell culture dishes and differentiated²⁵ by culturing in the same medium with 100 mM Phorbol 12-myristate 13-acetate (PMA, Sigma, Saint-Quentin Fallavier, France) for 48 h. Before the experiments the medium was replaced with a PMA-free medium. HEK293(β3) cells, a human embryonic kidney cell line stably transfected with the human β3 integrin gene (kindly provided by J-F. Gourvest, Aventis, France), were cultured as described in²⁶ in DMEM supplemented with 1% glutamine, 10% FBS and 700 µg/mL Geneticin (G418 sulfate, Gibco, Paisley, United Kingdom). Both types of cells were incubated with DiD-labelled LNCs and LNEs with the same fluorescence intensity. After 15 min or 1.5 h incubation at 37 °C, the cells were washed, trypsinized and analyzed by FACS (LSRII, Becton Dickinson, San Jose, USA). The results are presented as DiD histogram counts. Experiments were performed in triplicate.

In vivo distribution

Female NMRI nude mice (6–8 weeks old, Janvier, Le Genest-Saint-Isle, France) were injected subcutaneously with 10×10^6 HEK293(β3) cells/mouse ($n = 6$ /group). After tumor growth (6 weeks), anesthetized mice (isoflurane/oxygen 3.5%–4% for induction and 1.5%–2% thereafter, CSP, Cournon, France) were injected in the tail vein with 200 µL of DiD-containing particles

Nanocarrier type	PEG chain length (Da)	Diameter (nm)	PDI	ζ-Potential (mV)
LNC 25	660	24±2	0.07	-2±2
LNC 50	660	50±1	0.03	-3±1
LNC 100	660	102±1	0.05	-4±1
LNC 50	1500	44±2	0.16	-4±1
LNE 25	1980	26±1	0.17	-11±1
LNE 50	1980	50±1	0.19	-7±2
LNE 100	1980	87±2	0.25	-6±2
LNE 50	880	43±1	0.15	-10±2

Figure 2. Physico-chemical parameters. LNCs and LNEs differ from the length of the PEG chains covering their surface. The diameters, Polydispersity index and ζ -potentials of the nanocarriers (above), and size distributions of the nanocarriers prepared with PEG 660 Da (LNC) or PEG 1980 Da (LNE) (below) are presented.

suspension. Fluorescent images were acquired by a back-thinned CCD camera at -80°C (ORCAII-BT-512 G, Hamamatsu, Massy, France), 1.5 h, 3 h, 5 h and 24 h after injection. Three mice/group were sacrificed at 5 h and 24 h in order to image the organs and analyze the plasma. Image display and analysis were performed using the Wasabi software (Hamamatsu, Massy, France). Semi-quantitative data were obtained by drawing regions of interest (ROI) around each organ. All procedures and experimental protocols were approved by the ethical committee of Grenoble for the use of animal research.

The amount of injected particles was standardized and equalized according to their intensity of fluorescence. Additionally, injected concentrations of nanocarriers were adjusted in order to allow comparison with the complement activation test (mg of nanocarrier/mL serum; further converted to surface area of nanocarrier/mL serum). The total mouse blood volume was found to be 72 mL/kg and contained 55% serum. The injected nanocarrier concentrations were between 13 and 20 mg/mL, depending on the formulation, resulting in approximately 2.5–3.7 mg/mL serum *in vivo*. The studied range in the complement activation test was 0–6.25 mg/mL serum.

The ability of 50 nm LNCs and LNEs to accumulate into tumors was also tested. Four groups with 3 mice/group were

given subcutaneous tumors. We used human liver cancer (HUH-7, 5×10^6 implanted cells), HEK293($\beta 3$) (5×10^6 implanted cells), human glioblastoma (U87MG, 5×10^6 implanted cells), and murine breast cancer (TSA/pc, 10×10^6 implanted cells).

Confocal microscopy of frozen sections (7 μm) was carried out on an LSM710 LNO confocal microscope (Carl Zeiss, Jena, Germany) using a $40\times$ oil immersion objective of 1.0 N.A. The 633-nm laser was set up at 3% of its maximum intensity. Nuclei were labeled by 1 $\mu\text{g/mL}$ of Hoechst 33342 in PBS for 5 min RT.

Results

Preparation of LNCs and LNEs

The size distributions of the different formulations were homogeneous (Figure 2). LNCs were highly uniform (Polydispersity Indices (PDIs) less than 0.1), while LNEs had slightly higher PDIs (0.1–0.2). The ζ -potential for both nanocarriers was weakly negative. Consistent with previous studies,^{2,5} the formulations were stable for several months, except for the 50 nm LNCs with PEG 1500 chains, for which a temperature-dependent size increase was observed after one month of storage (1.9-fold (at 4°C) and 2.6-fold (at 37°C)).

Figure 3. Complement consumption (37°C) of the nanocarriers. (A) The effect of particle's size with LNCs (black) or LNEs (grey) on the complement consumption is presented as a function of the area of particles. We also positioned several flags ('e' for LNCs and 'e' for LNEs), which correspond to the amount of particles injected in mice in the rest of the study. (B) Effect of modification of the PEG length on the surface. LNCs with "short" PEGs of 660 Da or longer ones (1500 Da), as well as LNEs with short PEGs of 880 Da versus 1980 Da are studied.

Complement activation

Complement consumption was evaluated based on the lytic capacity of the serum on 50% of antibody-sensitized sheep erythrocytes (CH50 units) after exposure to LNCs and LNEs (Figure 3). PMMA nanoparticles of ± 150 nm, were used as positive, highly complement-activating controls. Indeed, they consumed 73% of the CH50 units when used at a concentration equivalent to a membrane surface of $1673 \text{ cm}^2/\text{mL}$. LNCs and LNEs only mildly activated the complement compared to PMMA and no major differences were seen between them: e.g., at $1700 \text{ cm}^2/\text{mL}$, CH50 consumptions were approximately 5%, 9% and 17% for 25, 50 and 100 nm particles, respectively. A clear correlation existed between the diameter of the particle and the amount of complement activation: increasing particle size from 25 to 100 nm increased complement activation. The CH50 unit consumption profiles were modified by exchanging the shorter PEG chain (660 or 880) for a longer one (1500 or 1980), while keeping the particle diameter constant (50 nm). A long PEG on the LNE surface lowered the CH50 unit consumption, while a short PEG caused the LNCs to have lower complement activation. Because the longer PEG did not benefit LNCs and rendered them unstable, the 50 nm LNCs with PEG 1500 were not included in subsequent tests. Similarly, because LNEs benefited from the longer PEG chain (1980 Da), LNEs with the shorter PEG chain (880 Da) were excluded from further in vitro tests. Encapsulation of fluorescent dyes in the LNCs and LNEs did not affect the complement activation profiles (data not shown).

Particle uptake by THP-1 macrophages and HEK293($\beta 3$) cells

Stealth particles are not expected to bind and to be internalized rapidly by cells. This was investigated in vitro by flow cytometry on THP-1 macrophages and HEK293($\beta 3$) cells at 37°C (Figure 4). All of the tested nanocarriers showed a barely detectable internalization by THP-1 (Figure 4, A). Only 100 nm LNCs were slightly more internalized at 1.5 h, but the intensities of fluorescence remained under the cut-off value (vertical lane), indicating weak staining. Similar results were obtained with the HEK293($\beta 3$) cells (Figure 4, B). In this case, 100 nm LNCs, as well as 50 and 100 nm LNEs, showed a very weak internalization.

In vivo distribution

LNCs of 25, 50 and 100 nm were homogeneously distributed and remained in the circulation for 24 h after intravenous injection (Figure 5, A). Liver accumulation was weak (regardless of the particle size), while elevated levels of fluorescence were detected in lymph nodes (left cervical lymph node). Plasma fluorescence measurements indicated significant quantities of circulating LNCs. Macroscopically, tumor accumulation was weak in the HEK293($\beta 3$) model, but the staining intensity of the cervical lymph node (LN) was similar to that observed in the liver. Importantly, this LN is not located on the tumor-bearing side of the mouse, which suggests that the particle accumulation in this LN was not due to tumor drainage. In addition, similar results were observed in *nude* mice without tumors, suggesting

that the LN tropism of these LNCs is not related to tumor-mediated activation of the LN. Histologic analysis of these lymph nodes demonstrated that most of the signal was located in the trabeculae and paracortex of the lymph nodes, without major observable differences between the different particles (data not shown).

The biodistribution patterns differed when the experiments were performed with 25 to 100 nm LNEs (Figure 5, B). The skin staining and hepato-biliary evacuation were more pronounced with the smallest LNEs. Liver uptake of the LNEs was low and not affected by LNE's size, while the lymph nodes showed positive labeling. Apart from this difference, the 50 and 100 nm LNEs performed similarly to the LNCs. Lastly, replacing PEG1800 by PEG900 did not modify the biodistribution. But the fluorescent signal was weaker even though the quantities of injected fluorescence were similar.

Tumor accumulation

As presented in Figure 5, tumor accumulation of LNCs and LNEs did not differ significantly when evaluated in the HEK293($\beta 3$) model. This was verified on tumor sections and confocal microscopy (Figure 6). The fluorescent signal was always observed, in particular in the periphery of the tumors. The staining was enriched in and around tumor blood vessels but also within the tumor nodules themselves. According to their proximity with the nuclei, fluorescent inclusions were observed in the cytoplasm of tumor and stromal cells as well as in the interstitium space. No major differences are observed between LNEs and LNCs or between 25, 50 or 100 nm large emulsions.

To evaluate the effect of tumor type on particle accumulation, one nanocarrier size (50 nm) was tested on different tumors. Accumulation of particles in the tumors was similar, regardless of the nanocarrier type (LNC/LNE). Instead, the accumulation significantly differed between tumor types, while exhibiting consistent organ distribution profiles (Figure 7). Similar to HEK293($\beta 3$), HUH-7 tumors presented poor particle accumulation (poor EPR effect). In comparison, both U87MG and TSA/pc tumors showed strong particle accumulation.

Discussion

LNCs were prepared by spontaneous formation of emulsion droplets driven by a temperature change, whereas LNEs were formed from a homogenization process by a high-energy source (sonication). Because of the spontaneous formation of LNCs, the quantity of the PEG-surfactant plays a more important role in the LNC fabrication process than in the LNE formulations. Indeed, the amount of Solutol decreased from 69% to 28% (of the overall content) as the LNC particle size increased from 25 to 100 nm, while the amount of Myrj 53 decreased from 58% to 34% in LNEs (see supplementary Table 1). Spontaneous particle formation without a homogenization step resulted in narrower size distributions (lower PDIs) (Figure 2), as previously observed for polymeric nanoparticles formed either spontaneously (nanoprecipitation) or after homogenization (emulsification techniques).²⁷ Particle size selection (25, 50 and 100 nm) for this study was decided according to two factors: we wanted

Figure 4. In vitro uptake by THP-1 macrophages (**A**) and HEK293(β_3) cells (**B**), after 15 min and 1.5 h of incubation at 37°C ([DiD]=0.2 μ M). The vertical line represents the positive cut-off value. All particles tested are poorly internalized by macrophages and HEK293(β_3) cells in vitro, even after 1.5 h of incubation at 37 °C, indicating that they are really “stealth”.

Figure 5. In vivo biodistribution of LNC (A) and LNE (B) in HEK293(β 3) xenografted *nude* mice. Three sizes of LNCs and LNEs and two sizes of PEGs for LNE 50 nm were studied. Fluorescence images (200 ms integration time) are recorded at different times after injection and superimposed to visible light images (white and black) (a and d). Fluorescence images are then performed on isolated organs 24 h after injection (an example of organs extracted from a mouse treated with LNC 50 nm is presented in (b)). ROIs are then defined on the extracted organs in order to semi-quantify the amount of photons detected per pixels after a 100 ms exposure. The results of these measurements in each organ and in the plasma are presented in (c) for LNCs and in (e) for LNEs.

to test the extremities of the available size range (25, 100 nm) together with an intermediate size (50 nm), and on the other hand, studies made with a phase diagram of LNCs provided the narrowest size distributions for these three sizes.³ The PEG

chains on the surface created a nearly neutral charge, while stabilizing the particles by steric repulsion. The observed slightly negative ζ -potentials could be explained by the presence of a small proportion of hydrolyzed surfactants, leading to a few

Figure 6. Subcutaneous HEK293($\beta 3$) tumors were extracted and cryo-sectioned before confocal microscopy observation. In blue: Hoechst staining of the nuclei. In red: DiD signal. No major differences can be detected in the distribution and intensity of the different nanoparticles within the tumor.

negatively charged polar groups.²⁸ Considering the theoretical calculations of particle quantities (see Materials and Methods), and that all of the PEG surfactants introduced were incorporated into particles, the PEG densities (mol/m^2) were lower on the LNE surface as compared to the LNCs, regardless of size (Supplementary Figure 1). This difference in surfactant densities is compensated for by the difference in PEG chain length (LNC: 660 Da, LNE: 1980 Da), providing one major difference between LNCs and LNEs.

In their “standard” formulations, LNCs are prepared with Solutol (PEG 600 Da), while LNEs are made with Myrj 53 (PEG 1980 Da) to provide satisfying pharmacokinetics.^{2,19} In this study, LNEs were also prepared with shorter PEG chains (880 Da), while an increased PEG length (1500 Da) was explored in LNC formulations. However, the LNCs with SPEG 1500 were not stable. For the longer PEG chains, no phase inversion zone (from w/o to o/w) was observed; instead, a transition from an o/w emulsion to a multiple w/o/w emulsion was seen.²⁹ This formation mechanism left a

remarkable amount of PEG stearate 1500 micelles that did not participate in LNC formation in the dispersion medium. During storage, these structures dissolved and adsorbed on the LNC surface, causing a size increase. Removal of the excess PEG 1500 surfactant was not possible: dialysis could not eliminate the excess material, and other methods such as size exclusion chromatography, led to particle destruction (not shown). Longer PEG chains could be attached to the LNC surface, but this step would require a post-modification procedure.¹³ In comparison, LNEs could use a wider variety of PEG surfactants. This versatility comes from the fact that they are not self-assembled emulsions but require energy input (sonication) to process them and achieve their non-thermodynamically (but long-term kinetically) stable state.⁶

Macrophages can remove nanoparticles from the bloodstream after intravenous administration.³⁰ They do not directly identify the nanoparticles, but recognize specific opsonin proteins, such as complement proteins, adsorbed on their surface.³¹ The complement activation test was used to assess the capacity of

Figure 7. In vivo biodistribution of LNC 50 nm (A) and LNE 50 nm (B) in *nude* mice and evaluation of the EPR effect of the different tumors, 24 h after injection. Human liver cancer (HUH-7), human glioblastoma (U87MG), human embryonic kidney cells HEK293(β3) and murine breast cancer (TSA/pc).

the LNCs and LNEs to inhibit the adsorption of complement proteins on their surface. LNCs and LNEs weakly activated the complement system because their high-density PEGylated surface provided a good shield.²⁰ The longer PEG chains provided the LNEs with better protection against complement protein adsorption, but the longer PEG (SPEG 1500) caused higher CH50 unit consumption for the LNCs, which resulted from the instability (increased size) of these nanocapsules. Relatively higher amounts of lecithin (Lipoid) on the LNEs'

surface structure (Supplementary Figure 1) did not seem to provoke higher protein adsorption compared to LNCs.

Higher complement activation, associated with larger particle size, could be related to the reduced surface curvature of bigger particles that reduces the spatial mobility of the PEG chains (there is more space for the extremities of the PEG to move in the case of smaller particles) and thus facilitates complement adsorption.²⁴ It should be noted that the interfacial density of PEGylated surfactant is almost the same, regardless the particle

size (Supplementary Figure 1), and does not affect complement activation even though the proportion of PEG is higher in the smaller particles.

In vivo experiments were designed to have comparable parameters to evaluate the size, PEG chain length, and nanocarrier (LNE or LNC) effects on particle biodistribution. Particle concentrations were adjusted based on their fluorophore payload, which is a function of the particle volume. One particle of 100 nm has a surface area of 120,000 nm². Accordingly, 8 particles of 50 nm or 125 particles of 25 nm should be injected to obtain similar quantities of fluorophore, corresponding to $8 \times 30,000 = 240,000$ nm² or $125 \times 5000 = 625,000$ nm² of a particle's surface, respectively. Plotting the in vivo nanocarrier concentrations in the complement activation graph (Figure 3, A) showed that all particles consumed between 15% and 25% of the available CH50 units, except for the 25 nm LNEs, which consumed nearly 40% of the available CH50 units. The differences in the exact particle sizes and injected amounts explained this observed difference: the “25 nm” LNEs had diameters of 22 nm and 20 mg/mL concentration, while the “25 nm” LNCs had diameters of 28 nm and a concentration of 19.0 mg/mL. The difference might seem negligible but when it was converted to particle amount (see Materials and Methods), the difference was about 3.8×10^{14} particles. In the case of 50 and 100 nm nanocarriers, the differences between the in vivo injected LNCs and LNEs were less than 1×10^{12} particles. Thus, the difference in surface area available for protein adsorption was greater for the 25 nm LNEs than for the corresponding LNCs. Therefore, for delivering an equal amount of drug payload, the total surface area of the injected particles should only impact complement activation when using the 25 nm LNEs. No other particles showed surface area-dependent effects on complement activation. The higher drug payload in larger particles counteracts the disadvantage of their surface curvature, which could favor opsonin binding.

No differences of uptake by THP-1 macrophage were observed among the different nanocarriers. In both in vitro and in vivo studies, one goal was to retain the same fluorescence intensity regardless of the nanocarrier size. Because LNCs and LNEs were prepared with the same dye concentration in the oily core (1.2 mM), the particle quantity had to be increased with decreasing particle size, as discussed earlier. A larger quantity of smaller nanocarriers most likely compensated for a possible decrease in the uptake rate of the smaller particles. According to our previous studies, when LNCs (25–100 nm) were incubated at the same molar concentrations with macrophages, an increased uptake rate was observed with increasing particle size (and increased fluorescence).²⁴ Under the same conditions, HEK293(β3) cells showed similar, negligible uptake of the nanocarriers as seen in THP-1 cells, but as previously established, LNE internalization can be increased by attaching RGD-ligands.⁷

The biodistribution profiles of the nanocarriers presented minor but interesting variations due to their size and/or composition (Figure 5). At early times (1.5 h and 3 h), the 25 nm LNCs and LNEs presented elevated levels of fluorescence in the skin (“green” pseudo color of the animals treated with 25 nm nanocarriers as compared to the “blue” appearance of

those treated with larger nanocarriers). This may be explained by an augmented circulation of small particles in the capillaries of the skin and/or a “burst-release” of the hydrophobic DiD dye, which could be more pronounced with small nanocarriers. The released DiD could be captured by the skin and also evacuated by the hepatobiliary route. A pronounced accumulation of fluorescence with 25 nm LNEs was measured in the intestine and skin at 24 h, suggesting that, although both types of small particles circulate efficiently in the microcapillaries, the 25 nm LNEs may be more easily destabilized than LNCs and can release DiD in the skin and circulation.

It is accepted that small-sized nanoparticles have longer circulation times in blood.^{20,32,33} This is usually observed if particles >100 nm are compared with particles <100 nm. However, when nanoparticles with diameters between 10 and 100 nm are evaluated, the trend is not always obvious. For example, when PEGylated polyacrylate nanoparticles increased from 20 to 60 nm, the systemic clearance rate and liver accumulation decreased significantly.³⁴ Similarly, 25 nm polymer micelles exhibited much shorter circulation half-lives than 60 nm micelles.³⁵ In the latter study, the authors hypothesized that this observation was due to more efficient clearance of the smaller micelles by hepatobiliary excretion because ~70% of the (mouse) liver fenestrations are narrower than 100 nm. In another study, the longest blood half-life of 10–100 nm PEGylated gold nanoparticles was achieved by compromising between the particle size and PEG chain length, resulting in ~60 nm particles.³⁶ Our results with the 25 to 100 nm nanocarriers are consistent with previous studies showing constant (or sometimes even random) distribution profiles in different organs: no clear relationship between the particle size and the biodistribution profiles has been established.^{34–38} Biodistribution results from the current study are compatible with the in vitro complement activation and macrophage uptake evaluations, as no clear differences were observed between the types of nanocarriers. In addition, the PEG-containing surfaces of both LNCs and LNEs provide appropriate stealth properties for the nanocarriers.

Fluorescence imaging only allows the tracking of the (DiD) fluorophore in vivo, which might be different from that of the nanocarriers. However, despite the fact that the in vivo integrity of these lipid nanocarriers cannot be directly confirmed, free DiD dye displays different kinetics and biodistribution than that observed in these studies, and does not fluoresce in aqueous medium.¹⁹ Therefore, it is assumed that these results reflected the kinetics and biodistribution of the nanocarriers or of the DiD captured locally by tissues.

Tumor vasculature is irregular, leaky, dilated, and the vascular endothelial cells are poorly aligned with large fenestrations.^{39,40} This morphology results in increased leakage of macromolecules and nanocarriers out of the circulatory system into the tumor tissue by the EPR effect.^{41,42} Although Human Embryonic Kidney HEK293 cells form tumors in *nude* mice, they are not tumor cells but normal embryonic cells transformed with adenovirus 5 DNA. When injected subcutaneously in mice, they form a slow-growing tumor (~6 weeks to reach 5 mm),⁴³ resulting in well-structured, neo-angiogenic vasculature with tight endothelial junctions.^{26,44} Therefore, HEK293(β3) tumors

can be classified as “weak EPR” tumors. TSA/pc cells originate from chemically induced tumors in mice. They grow rapidly (~10 days to 5 mm), leading to leaky fenestrations.⁴⁵ Additionally, tumors from U87MG cells exhibit highly porous vasculature.⁴⁶ The results from the 50-nm LNCs and LNEs support these conclusions: significantly more nanocarriers were found in the TSA/pc and U87MG tumors, compared to the HEK293(β3) and HUH7 tumors. In addition, four independent experiments confirmed that the biodistribution of these nanocarriers was highly reproducible and homogenous. The particles stained the skin, liver, LNs and tumors. In summary, LNCs and LNEs showed good stealth properties and can target passively the lymph nodes and EPR “positive” tumors, which is promising for clinical applications.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.nano.2012.08.005>.

References

- Heurtault B, Saulnier P, Benoit JP, Proust JE, Pech B, Joel R. Lipid nanocapsules, preparation method and use as medicine. Edited by 2001, p.
- Heurtault B, Saulnier P, Pech B, Proust J-E, Benoit J-P. A novel phase inversion-based process for the preparation of lipid nanocarriers. *Pharm Res* 2002;**19**:875–80.
- Heurtault B, Saulnier P, Pech B, Venier-Julienne M-C, Proust J-E, Phan-Tan-Luu R, et al. The influence of lipid nanocapsule composition on their size distribution. *Eur J Pharm Sci* 2003;**18**:55–61.
- Goutayer M, Texier-Nogues I, Fattaccioli J, Bibette J. Fluorescent emulsions for optical imaging. Edited by 2008, p.
- Delmas T, Couffin A-C, Bayle PA, Fd Crécy, Neumann E, Vinet F, et al. Preparation and characterization of highly stable lipid nanoparticles with amorphous core of tuneable viscosity. *J Colloid Interface Sci* 2011.
- Delmas T, Piraux H, Couffin A-C, Texier I, Vinet F, Poulin P, et al. How to prepare and stabilize very small nanoemulsions. *Langmuir* 2011;**27**:1683–92.
- Goutayer M, Dufort S, Josserand V, Royère A, Heinrich E, Vinet F, et al. Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging. *Eur J Pharm Biopharm* 2010;**75**:137–47.
- Peltier S, Oger JM, Lagarce F, Couet W, Benoit JP. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. *Pharm Res* 2006;**23**:1243–50.
- Lacoeuille F, Hindre F, Moal F, Roux J, Passirani C, Couturier O, et al. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel. *Int J Pharm* 2007;**344**:143–9.
- Garcion E, Lamprecht A, Heurtault B, Paillard A, Aubert-Pouessel A, Denizot B, et al. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. *Mol Cancer Ther* 2006;**5**:1710–22.
- Cirpanli Y, Allard E, Passirani C, Bilensoy E, Lemaire L, Calis S, et al. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. *Int J Pharm* 2011;**403**:201–6.
- Lamprecht A, Saumet JL, Roux J, Benoit JP. Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment. *Int J Pharm* 2004;**278**:407–14.
- Morille M, Montier T, Legras P, Carmoy N, Brodin P, Pitard B, et al. Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. *Biomaterials* 2010;**31**:321–9.
- Morille M, Passirani C, Dufort S, Bastiat G, Pitard B, Coll JL, et al. Tumor transfection after systemic injection of DNA lipid nanocapsules. *Biomaterials* 2011;**32**:2327–33.
- Vanpouille-Box C, Lacoeuille F, Belloche C, Lepareur N, Lemaire L, LeJeune JJ, et al. Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules. *Biomaterials* 2011;**32**:6781–90.
- Vanpouille-Box C, Lacoeuille F, Roux J, Aube C, Garcion E, Lepareur N, et al. Lipid nanocapsules loaded with rhenium-188 reduce tumor progression in a rat hepatocellular carcinoma model. *PLoS One* 2011;**6**:e16926.
- Allard E, Hindre F, Passirani C, Lemaire L, Lepareur N, Noiret N, et al. 188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas. *Eur J Nucl Med Mol Imaging* 2008;**35**:1838–46.
- Goutayer M, Dufort S, Josserand V, Royère A, Heinrich E, Vinet F, et al. Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging. *Eur J Pharm Biopharm* 2010;**75**:137–47.
- Texier I, Goutayer M, Da Silva A, Guyon L, Djaker N, Josserand V, et al. Cyanine-loaded lipid nanoparticles for improved in vivo fluorescence imaging. *J Biomed Opt* 2009;**14**:054005.
- Vonarbourg A, Passirani C, Saulnier P, Benoit J-P. Parameters influencing the stealthiness of colloidal drug delivery systems. *Biomaterials* 2006;**27**:4356–73.
- Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. *J Control Release* 2000;**65**:271–84.
- Bellis SL. Advantages of RGD peptides for directing cell association with biomaterials. *Biomaterials* 2011;**32**:4205–10.
- Passirani C, Barratt G, Devissaguet J-P, Labarre D. Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. *Life Sci* 1998;**62**:775–85.
- Vonarbourg A, Passirani C, Saulnier P, Simard P, Leroux J-C, Benoit JP. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. *J Biomed Mater Res A* 2006;**78A**:620–8.
- Tsuchiya S, Kobayashi Y, Goto Y, Okumura H, Nakae S, Konno T, et al. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. *Cancer Res* 1982;**42**:1530–6.
- Jin Z-H, Josserand V, Foillard S, Boturyn D, Dumy P, Favrot M-C, et al. In vivo optical imaging of integrin $\alpha_v\beta_3$ in mice using multivalent or monovalent cRGD targeting vectors. *Mol Cancer* 2007;**6**:41.
- Quintanar-Guerrero D, Allémann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. *Drug Dev Ind Pharm* 1998;**24**:1113–28.
- Ohshima H. Electrokinetics of soft particles. *Colloid Polym Sci* 2007;**285**:1411–21.
- Béduneau A, Saulnier P, Anton N, Hindré F, Passirani C, Rajerison H, et al. Pegylated nanocapsules produced by an organic solvent-free method: evaluation of their stealth properties. *Pharm Res* 2006;**23**:2190–9.
- Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanoparticles. *Science* 1994;**263**:1600–3.
- Frank MM, Fries LF. The role of complement in inflammation and phagocytosis. *Immunol Today* 1991;**12**:322–6.
- Dufort S, Sancey L, Coll JL. Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. *Adv Drug Deliv Rev* 2011;**64**:179–89.
- Lux F, Mignot A, Mowat P, Louis C, Dufort S, Bernhard C, et al. Ultrasmall rigid particles as multimodal probes for medical applications. *Angew Chem Int Ed Engl* 2011;**50**:12299–303.
- Yang Z, Leon J, Martin M, Harder JW, Zhang R, Liang D, et al. Pharmacokinetics and biodistribution of near-infrared fluorescence polymeric nanoparticles. *Nanotechnology* 2009;**20**:165101.

35. Lee H, Fonge H, Hoang B, Reilly RM, Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. *Mol Pharm* 2010;**7**:1195-208.
36. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW. Mediating tumor targeting efficiency of nanoparticles through design. *Nano Lett* 2009;**9**:1909-15.
37. Meng H, Xue M, Xia T, Ji Z, Tarn DY, Zink JJ, et al. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. *ACS Nano* 2011;**5**:4131-44.
38. Sun X, Rossin R, Turner JL, Becker ML, Joralemon MJ, Welch MJ, et al. An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on *in vivo* biodistribution. *Bio-macromolecules* 2005;**6**:2541-54.
39. Baban DF, Seymour LW. Control of tumour vascular permeability. *Adv Drug Deliv Rev* 1998;**34**:109-19.
40. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. *Br J Cancer* 2001;**84**:1354-62.
41. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumorotropic accumulation of proteins and the antitumor agent Smancs. *Cancer Res* 1986;**46**:6387-92.
42. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. *Adv Drug Deliv Rev* 2011;**63**:136-51.
43. Dufort S, Sancey L, Hurbin A, Foillard S, Boturyn D, Dumy P, et al. Targeted delivery of a proapoptotic peptide to tumors *in vivo*. *J Drug Target* 2011;**19**:582-8.
44. Razkin J, Josserand V, Boturyn D, Z-h Jin, Dumy P, Favrot M, et al. Activatable fluorescent probes for tumour-targeting imaging in live mice. *ChemMedChem* 2006;**1**:1069-72.
45. Sancey L, Ardisson V, Riou L, Ahmadi M, Marti-Batlle D, Boturyn D, et al. *In vivo* imaging of tumour angiogenesis in mice with the $\alpha v \beta 3$ integrin-targeted tracer ^{99m}Tc -RAFT-RGD. *Eur J Nucl Med Mol Imaging* 2007;**34**:2037-47.
46. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. *Proc Natl Acad Sci U S A* 1998;**95**:4607-12.